Core Viewpoint - The report maintains a "Buy" rating for King’s Ray Biotechnology (01548) with a target price of HKD 26.21 per share, emphasizing the company's long-term growth strategy driven by technology and global expansion [1] Group 1: Long-term Strategic Planning - The company aims to become the global leader in biopharmaceuticals (antibody drugs, gene & cell therapy) and synthetic biology services and products, with a focus on solid cash flow to support its life sciences and biopharmaceutical CRDMO foundations [1] - The long-term revenue target is set at USD 3 billion by 2035, with an operating profit margin exceeding 20% [1] Group 2: Business Growth and Market Position - The gene & plasmid business has achieved continuous growth, aiming to expand downstream applications to enhance business potential and support further growth [2] - The antibody protein business seeks to strengthen core competitiveness and achieve market leadership by exploring non-outsourcing markets and providing innovative instruments and solutions [2] - The protein antibody drug CDMO aims to capitalize on the rebound of China's biotechnology sector, accumulate more projects and capabilities, and enhance sales in Europe and the U.S. to expand high-margin revenue sources [2] Group 3: Growth Opportunities and Product Development - The company plans to integrate its business capabilities (life sciences + thriving biology) to transform mature services into one-stop solutions, accelerating productization for downstream clients [3] - Focus areas include high-margin products in enzyme preparations, such as starch sugar, alcohol, and home care, while seeking explosive industry opportunities through innovative protein/enzyme products [3] Group 4: Financial Forecast and Valuation - The company’s revenue projections for the main business segments from 2025 to 2027 are USD 939 million, USD 825 million, and USD 961 million, with year-on-year growth rates of 58%, -12%, and 16% respectively [4] - The valuation method applied is based on a PS multiple of 6 times the projected 2026 revenue, leading to a main business valuation of RMB 35.2 billion [4] - The fair value of the company's stake in Legend Biotech, a U.S.-listed company, is estimated at RMB 17 billion as of November 20, 2025 [4]

内容概况：弹性蛋白（Elastin）广泛存在于哺乳动物结缔组织，和胶原蛋白同为皮肤的重要组成部分， 胶原蛋白提供支撑作用，而弹性蛋白提供延展性与回弹性。2024年，中国弹性蛋白行业市场规模约为 6.27亿元，同比增长3.81%。其前体原弹性蛋白（tropoelastin）胞内合成后分泌到胞外，经酶催化交联 成为高度不溶的弹性蛋白网络，使弹性蛋白分子能够任意卷曲，具有高弹性。在应用领域，弹性蛋白通 常与胶原蛋白、透明质酸等成分复配作为护肤品成分以达到综合抗老化效果。其良好的生物相容性和弹 性能使其成为理想的生物医用材料，包括人工血管、创伤敷料、药物递送、伤口修复等多个方面。近年 来弹性蛋白主要用于补剂、化妆品、生物医药等领域，逐渐成为新的热点产品。 相关上市企业：丸美生物（603983） 二、行业产业链 相关企业：内蒙古伊利实业集团股份有限公司、山东得利斯食品股份有限公司、黑龙江宾西牛业有限公 司、温氏食品集团股份有限公司、牧原食品股份有限公司、新希望六和股份有限公司、北京大北农科技 集团股份有限公司、上海药明康德新药开发有限公司、深圳华大基因股份有限公司、苏州泓迅生物科技 股份有限公司、梅花生物科技集团股份有 ...

Core Viewpoint - The basic chemical and chemical products industry is experiencing a diversified development trend, with various segments showing growth potential due to market dynamics and policy influences [1] Group 1: Industry Trends - The third-generation refrigerants are entering a high prosperity cycle, with supply constrained by quota policies and demand benefiting from the growth in heat pumps, cold chains, and Southeast Asian markets [1] - Synthetic biology is seizing development opportunities under energy structure adjustments, with the cost of bio-based materials decreasing, leading to an explosive demand [1] - The domestic production process of COC polymers is accelerating, with applications expanding in optical and packaging fields [1] - Light hydrocarbon chemistry is becoming a global trend in the olefin industry, aligning with carbon neutrality goals due to its low-carbon characteristics [1] - Potash fertilizer prices have bottomed out and are recovering, supported by production cuts from international giants and improved planting intentions [1] - The MDI industry is seeing a favorable supply structure, with high technical barriers and steady demand supporting long-term development [1] Group 2: Investment Insights - The chemical leader ETF (516220) tracks a segmented chemical index (000813), which selects listed companies involved in sub-industries such as pesticides, fertilizers, and coatings to reflect the overall performance of leading and well-growing companies in the chemical field [1]

Mergers and Acquisitions - Chenyi Intelligent plans to acquire 55% of Huaze Electronics through cash payment [1] - Beijiete's wholly-owned subsidiary intends to acquire 55% of Dahao Mining for 225 million yuan [1] Share Buybacks and Equity Transfers - Chenzhan Optoelectronics' controlling shareholder is transferring 5.02% of shares [2] - Huamin Co., Ltd. plans to transfer 5.17% of shares by Jianxianghuihong [2] - Pro Pharmaceutical intends to repurchase shares worth between 180 million to 360 million yuan, with a maximum price of 23 yuan per share [2] - Ganyue Expressway's actual controller will change from the Provincial Department of Transportation to the Provincial State-owned Assets Supervision and Administration Commission [2] External Investments and Daily Operations - Hefei China has completed its suspension review and resumed trading [3] - Dwei Co., Ltd. is advancing the procedures for lithium battery new energy projects in Hunan Chenzhou [4] - Desay SV plans to launch an AI computing terminal for the robotics sector [4] - Neusoft Group received a notification from a major domestic automotive manufacturer to supply intelligent cockpit domain controllers, with a total expected supply amount of 4.2 billion yuan [4] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision, acquiring 60% ownership post-investment [5] - Dongfang Electric intends to invest 910 million yuan to hold 49% in a joint venture [6] - Bailian Group's subsidiary plans to transfer 100% of its stake in Yangpu Century Bailian for 78.286 million yuan [6] - Ruisheng Intelligent's subsidiary won a bid for a China Mobile ICT project, focusing on computing server hardware and systems [6] - Zhifei Biological's clinical trial application for the ZFA01 adjuvant vaccine has been accepted [7] - Haizheng Pharmaceutical's subsidiary is collaborating with East China Institute on a biomanufacturing project for heparin [8] - Baiyang Pharmaceutical's Zap Therapeutic plans to invest 4.9 million USD in Baiyang Sap to expedite the clinical introduction of the ZAP-X Mars surgical robot [8] - Jinbei Automotive plans to invest 5.8 billion yuan and purchase equity in Changchun Zhongtuo Molding Technology [9] - Baili Tianheng has secured a commitment from Bank of China Sichuan Branch for a total of no less than 8 billion yuan in comprehensive credit support [10]

Core Viewpoint - The article highlights the emergence of recombinant collagen as a significant anti-aging ingredient developed in China, marking a shift in the beauty industry where domestic brands gain authority in core raw materials, moving from a follower to a leader position in the global market [3][4][5]. Group 1: Company Overview - Marubi Biotech is one of the few companies in China that has achieved full-chain self-research and production of recombinant collagen, positioning itself as a representative of high-end beauty technology in the country [5][6]. - The company has played a crucial role in establishing national industry standards for recombinant collagen, transitioning from an industry participant to a standard setter, which signifies its technical authority [6][7]. Group 2: Technological Advancements - Marubi has developed a comprehensive research and production chain in the functional protein field, including gene editing, fermentation expression, structural verification, separation purification, and formula application [7][11]. - The establishment of the "National Recombinant Functional Protein Technology Research Center" under Marubi indicates its capability to not only serve its product development but also provide technical output to the industry [11][12]. Group 3: Product Development and Efficacy - Marubi's products, such as the "Recombinant Double Collagen," have achieved significant breakthroughs, including the first global production of high-activity recombinant human collagen through self-research and the use of translation pause technology [13][14]. - Clinical trials have shown that Marubi's products can effectively reduce wrinkle volume, with a reported 56.83% reduction in under-eye wrinkles and 13.18% in nasolabial folds after seven days of use [17][20]. Group 4: Market Strategy and Future Outlook - Marubi aims to establish a global presence by setting up research centers abroad and forming joint ventures, reflecting a shift from merely exporting products to a more comprehensive output of technology, standards, and brand culture [28][29]. - The company's vision includes creating a beauty standard that transcends cultural boundaries, emphasizing the importance of scientific research and long-term commitment to quality over short-term gains [28][30].

Core Viewpoint - Haizheng Pharmaceutical (600267) announced a collaboration with East China Synthetic Biology Industry Technology Research Institute to develop and industrialize bioengineered heparin drugs using synthetic biology, with a project contract amount not exceeding 120 million yuan [1] Group 1 - The collaboration aims to enhance the company's product coverage in the field of synthetic biology [1] - The project is expected to promote the development of the synthetic biology industry [1] - The total contract amount for the project is capped at 120 million yuan [1]

Group 1 - The core viewpoint of the article is that Huaxi Biological has disclosed a new patent technology for specific sequence PDRN, which is a significant advancement in the field of synthetic biology [1] - The newly patented product features a specific sequence PDRN that is 100% similar to the human genome, ensuring stability and controllability in molecular weight and product quality [1] - This achievement marks a breakthrough over previous methods that relied on animal extraction and microbial fermentation, providing a more stable raw material source and significantly improved purity [1] Group 2 - In Q3 2025, the company continued to maintain profit growth, with a revenue of 3.163 billion, down 18.36%, and a net profit attributable to shareholders of 252 million, down 30.29% [2] - The Q3 revenue was 903 million, down 15.16%, but the net profit attributable to shareholders increased by 55.63% to 32 million, indicating a positive trend following a profitability turning point in Q2 [2] - The gross profit margin in Q3 was 69.91%, down 2.47 percentage points, while the sales expense ratio decreased to 34.26%, the lowest in five years, due to optimized brand communication and channel structure [2]

Industry Overview - The chemical sector's overall performance ranked 9th this week (2025/11/10-2025/11/14) with a change of 2.61%, outperforming the Shanghai Composite Index by 2.79 percentage points and the ChiNext Index by 5.62 percentage points [1] - The chemical industry is expected to continue its differentiated trend in 2025, with a focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [1] Synthetic Biology - The arrival of a pivotal moment in synthetic biology is anticipated, driven by the adjustment of energy structures, which may disrupt fossil-based materials and favor low-energy products [1] - Traditional chemical companies are expected to compete on energy consumption and carbon tax costs, with successful firms leveraging green energy and integrated advantages to reduce costs [1] - The demand for bio-based materials is projected to surge, leading to potential profitability and valuation increases for companies in this sector, such as Kasei Bio and Huaheng Bio [1] Refrigerants - The implementation of quota policies is expected to usher in a high-growth cycle for third-generation refrigerants, with supply entering a "quota + continuous reduction" phase starting in 2024 [2] - The demand for refrigerants is anticipated to grow due to the development of heat pumps, cold chain markets, and the expansion of the air conditioning market, particularly in Southeast Asia [2] - Companies with a high quota share, such as Juhua Co., Sanmei Co., Haohua Technology, and Yonghe Co., are expected to benefit significantly [2] Electronic Specialty Gases - Electronic specialty gases are critical to the electronics industry, characterized by high technical barriers and added value [3] - The domestic market faces a mismatch between rapid upgrades in wafer manufacturing and insufficient high-end electronic specialty gas capacity, presenting opportunities for domestic replacements [3] - Companies like Jinhong Gas, Huate Gas, and China Shipbuilding Gas are positioned to capitalize on this demand [3] Light Hydrocarbon Chemicals - The trend towards light raw materials in the global olefin industry is becoming more pronounced, with a shift from heavy naphtha to lighter low-carbon alkanes like ethane and propane [4] - Light hydrocarbon chemicals are favored for their low carbon emissions, low energy consumption, and low water usage, aligning with global carbon neutrality goals [4] - Companies in the light hydrocarbon sector, such as Satellite Chemical, are expected to see a revaluation of their worth [4] COC Polymers - The industrialization of COC/COP (cyclic olefin copolymer) is accelerating in China, driven by domestic companies overcoming previous R&D challenges [5] - The shift of downstream industries like consumer electronics and new energy vehicles to domestic production is enhancing the demand for COC/COP materials [5] - Companies like Acolyte are recommended for their potential in the COC polymer production segment [5] Potash Fertilizers - Potash fertilizer prices are expected to rebound as the industry enters a destocking cycle, with supply reductions from major players like Canpotex and Nutrien [6] - The termination of the Black Sea Grain Export Agreement has led to increased prices for wheat and corn, boosting the demand for potash fertilizers [6] - Companies such as Yara International, Salt Lake Potash, and Zangge Mining are highlighted as key players in this sector [6] MDI Market - The MDI market is characterized by oligopoly, with demand steadily increasing due to the expansion of polyurethane applications [7] - Major global manufacturers, including Wanhua Chemical, BASF, Covestro, Huntsman, and Dow, control over 90% of MDI production capacity [7] - Despite current price pressures, MDI is expected to maintain profitability, with a positive outlook as demand recovers [7] Chemical Price Tracking - The top five price increases this week included dimethylcyclosiloxane (DMC) at 18.18%, sulfur at 8.96%, and NYMEX natural gas at 5.82% [8] - The top five price decreases included butadiene at -7.89% and hydrofluoric acid at -4.27% [8] Supply Side Tracking - This week, 164 chemical enterprises reported production capacity changes, with 11 new repairs and 5 restarts noted [9]

Group 1 - The article emphasizes the strategic importance of biological manufacturing as a key industry for future development, highlighted by its inclusion in the 15th Five-Year Plan alongside quantum technology and 6G [2] - The upcoming "SynBio China Fourth Synthetic Biology and Biomanufacturing Conference" will take place in Shenzhen on January 8-9, 2026, focusing on industrialization technology challenges and providing comprehensive solutions for intelligent manufacturing and green production [3][2] - The conference aims to gather experts from academia and industry to analyze the entire process of "design-build-test-learn" in synthetic biology, addressing the optimization and innovation opportunities in various industrialization stages [2] Group 2 - The conference is expected to host around 1,000 participants, indicating significant interest and engagement in the field of synthetic biology and biomanufacturing [3] - There are opportunities for exhibitors from synthetic biology and modern biotechnology sectors to showcase their products and technologies at the conference [9] - Registration for the conference is currently free but limited, emphasizing the need for early registration to secure participation [12]

Core Insights - The article highlights the upcoming "SynBio China Fourth China Synthetic Biology and Biomanufacturing Conference" scheduled for January 8-9, 2026, in Shenzhen, emphasizing the importance of biomanufacturing in future industries [4][8]. Group 1: Conference Details - The conference will feature Dr. Zhang Dongyuan, Chairman of Zhongke Kangyuan (Tangshan) Biotechnology Co., Ltd., who will present a report on the key technologies for the depolymerization of non-grain biomass [2][4]. - The event aims to gather 1,000 participants from various sectors, including academia and industry, to address challenges in industrialization technology [8]. Group 2: Background and Significance - The conference is positioned within the context of China's strategic focus on biomanufacturing as a critical area for future development, alongside quantum technology and 6G [7]. - The article discusses the challenges of crossing the "valley of death" in biomanufacturing, highlighting opportunities for optimization and innovation in various industrialization processes [7]. Group 3: Technological Innovations - Zhongke Kangyuan has developed a comprehensive technology system for biomass depolymerization over seven years, including key technologies such as a continuous oxidation depolymerization system and a high-solid continuous fermentation system [4]. - The company has successfully established China's first production line capable of processing 200,000 tons of straw protein and digestible sugars [4].